Washington Dc, DCNCT07089121Now EnrollingIRB Ready

Childhood-onset Systemic Lupus Erythematous Clinical Trial in Washington Dc, DC

Access cutting-edge childhood-onset systemic lupus erythematous treatment through this phase 1/2 clinical trial at a research site in Washington Dc. Study-provided care at no cost to qualified participants.

Sponsored by Cartesian Therapeutics

Quick Self-Assessment

See if you qualify for this Washington Dc location

Preparing your pre-screening questions…

Expert Care in Washington Dc

Access childhood-onset systemic lupus erythematous specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related childhood-onset systemic lupus erythematous treatment provided free

Apply for This Washington Dc Location

Check if you qualify for this childhood-onset systemic lupus erythematous clinical trial in Washington Dc, DC

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Washington Dc

    Convenient for DC residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Washington Dc site if eligible
  4. 4Begin participation

About This Childhood-onset Systemic Lupus Erythematous Study in Washington Dc

Safety, tolerability and efficacy of Descarte-08 in children, adolescents and young adults with childhood-onset systemic lupus erythematosus, ANCA-associated vasculitis, juvenile myasthenia gravis, and juvenile dermatomyositis

Sponsor: Cartesian Therapeutics

Who Can Participate

Inclusion Criteria

At least age 12
definitive diagnosis of childhood-onset systemic lupus erythematous, juvenile Myasthenie gravis, juvenile dermatomyositis and AAV
Signs and symptoms of moderate disease
History of systemic treatment
Parent/Guardian/Patient must be able to give written informed consent

Exclusion Criteria

Major chronic illness that is not well managed at the time of study entry and in the opinion of the investigator may increase the risk to the patient;
Abnormal PT/INR or PTT increased \> 1.5-fold or patient is on anticoagulation therapy (except in cases of elevated PTT with documented lupus anticoagulant; or in patients who have been on stable doses of anticoagulation therapy for more than 6 months of VTE diagnosis; or in patients on stable doses of anticoagulation therapy for at least 8 weeks of atrial fibrillation diagnosis; these conditions will not be exclusionary unless, in the investigator's opinion, they make participation in the study unsafe);
ANC \< 1000 cells/microliter ;
Hemoglobin \< 8.0 g/dL ;
Platelets \< 50,000/mm3 (NOTE: platelet transfusions are permissible);
ALT and/or AST with GGT ≥ 3× upper limit of normal
Creatine Clearance less than 30mL/min /1.73 m2;
History of primary immunodeficiency, organ, or allogeneic bone marrow transplant;
Patients must be seronegative for hepatitis B surface antigen;
Patients must be seronegative for hepatitis C antibody. If hepatitis C antibody test is positive, then patients must be tested for the presence of viremia by RT-PCR and must be HCV RNA negative;
History of positive HIV or positive HIV at screening;
Active tuberculosis or positive QuantiFERON test at screening;
Any other laboratory abnormality that, in the opinion of the investigator, may jeopardize the subject's ability to participate in the study; 23. Any active significant cardiac or pulmonary disease not related to the primary indication as determined by principal investigator and medical monitor Note: Patients with asthma and COPD controlled with inhaled medications are allowed; 24. Any arterial or venous thromboembolic events in the past 3 months; 25. History of malignancy that required treatment in the past 3 years except for successfully-treated squamous cell and/or basal cell carcinoma of the skin and/or breast or colon cancer that is surgically removed and did not require adjuvant chemotherapy or radiotherapy; 26. Treatment with any investigational agent within 4 weeks of screening or 5 half-lives of the investigational drug (whichever is longer); 27. Receipt of a live vaccination within 4 weeks prior to baseline (Day 1) or intent to receive live vaccination during the study (Note: mRNA-based vaccines such as those against SARS-CoV-2 are not considered live; likewise, the Janssen Covid-19 vaccine is not live); 28. History of significant recurrent infections or any active infection that may interfere with the patient's participation in the opinion of the investigator; 29. Any known psychiatric illness that may interfere with the patient's participation in the study in the opinion of the investigator.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Washington Dc?

Yes, this clinical trial (NCT07089121) has an active research site in Washington Dc, DC that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Childhood-onset Systemic Lupus Erythematous Treatment Options in Washington Dc, DC

If you're searching for childhood-onset systemic lupus erythematous treatment options in Washington Dc, DC, this clinical trial (NCT07089121) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Washington Dc research site is actively enrolling participants for this phase 1/2 clinical trial. You'll receive care from experienced childhood-onset systemic lupus erythematous specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all childhood-onset systemic lupus erythematous clinical trials near you to find additional studies recruiting in your area.

More Heart Attack Trials in Washington Dc, DC

See all heart attack clinical trials recruiting in Washington Dc — not just this study.

Browse Heart Attack Trials in Washington Dc →

Browse More Trials by Condition

Heart Attack TrialsEssential Tremor TrialsLupus TrialsInterstitial Cystitis TrialsSystemic Lupus Erythematosus TrialsMyocardial Infarction TrialsInterstitial Lung Disease TrialsAll Conditions →

Ready to Join in Washington Dc?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Washington Dc, DC